Periocular involvement is an uncommon manifestation of discoid lupus that is often difficult to treat due to its resistance to systemic medications and the inherent challenges of applying topical medications. It commonly affects the lower lid margin causing blepharitis and madarosis as well as significant cosmetic distress. Current treatment options include oral hydroxychloroquine, methotrexate, topical corticosteroids, topical tacrolimus or intralesional steroids, often with an unsatisfactory response. Here we report a case of a 55 year old Hispanic female with longstanding and isolated periocular discoid lupus who was successfully treated with cyclosporine ophthalmic emulsion. The patient first presented 10 years ago with lower eye lid erythema and madarosis. Antibodies including ANA by immunofluorescence, anti-Ro, and anti-La were negative. Over the course of 10 years she experienced an incomplete response with multiple therapies including anti-malarials, thalidomide, and mycophenolate mofetil. Subsequently, the patient underwent adjuvant treatment with cyclosporine ophthalmic emulsion with progressive resolution of periocular DLE over a course of 12 months. Cyclosporine is a calcineurin inhibitor that inhibits T cell mediated immune response, which plays an important role in lupus pathogenesis. The ophthalmic emulsion form, commercially branded as Restasis, is commonly used to treat patients with Sjogren’s disease and Sicca symptoms. Other calcineurin inhibitors including tacrolimus and pimecrolimus are established treatments for patients with cutaneous lupus. These medications function by inhibiting IL-12 mediated T cell activation and production of cytokines including IL-2, IL-10 and interferon gamma, all of which play important roles in CLE. The use of cyclosporine ophthalmic emulsion in treating periocular lesions has not been reported before. Our case suggests that intraocular T cell inhibitors such as cyclosporine may be helpful adjuvants in the treatment of recalcitrant periocular discoid lupus.